Novo Nordisk (NVO) stock decreased by 4.6% on Thursday, September 25th. The company lowered its full-year outlook for 2025 compared to the outlook issued in May. For 2025, the range for sales growth is now expected to be 8% to 14% at constant exchange rates or 11% at the midpoint. The reasons for lowering growth expectations are based on lower growth expectations for VIGOVI and Ozempic in the U. S. obesity market and the U. S. GLP-one market, persistent use of compounded GLP-one, and slower market expansion and competition. Despite the expiry of the FDA grace period for mass compounding on 05/22/2025, Novo Nordisk market research shows that the unsafe and unlawful mass compounding has continued, resulting in multiple providers continuing to market and sell compounded GLP-1s. In response, Novo Nordisk is pursuing litigation to protect patients. There is an expectation to launch an oral version, or pill version, in the next few months. The presenter increased the intrinsic value per share to $136.67. The actual price is $56.04